UICMEW | Post Test, Evaluation and Claim Credit UICMEW | Session 1 - Post Test January 15, 2025 University of Illinois Cancer Center Winter CME Series Session 1: Hematologic Malignancies Please enter your information: First Name * Last Name * Degree * Institution * Email * City * State * 1. Which of the following is a key advantage of bispecific T-cell engagers in the treatment of Non-Hodgkin Lymphoma (NHL)? * A. Direct targeting of leukemic stem cells B. Simultaneous engagement of T cells and cancer cells C. Stimulation of minimal residual disease (MRD) response D. 87M with new D. Inhibition of tyrosine kinase pathwaysof metastatic castrate-sensitive prostate cancer 2. What is the role of minimal residual disease (MRD) in managing multiple myeloma (MM)? * A. Identifying potential CAR T-cell candidates B. Determining the stage of relapse in MM patients C. Guiding therapeutic decisions across disease progression D. Assessing response to tyrosine kinase inhibitors 3. Which of the following represents a recent advancement in CAR T-cell therapy for hematologic malignancies? * A. Reduced infusion-related adverse events B. Use in both relapsed and newly diagnosed cases C. Application in solid tumor treatment D. Targeting of refractory B-cell leukemias 4. Why is education on novel treatment protocols for Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) important? * A. To enhance clinicians’ ability to detect MRD B. To facilitate the inclusion of CAR T-cell therapies in initial treatments C. To support personalized treatment plans incorporating novel therapies D. To improve stem cell transplant success rates 5. What is a primary challenge in implementing advancements in bispecific T-cell engagers and CAR T-cell therapies? * A. High rates of systemic toxicity B. Lack of FDA approvals for these therapies C. Limited knowledge of treatment selection and adverse event management D. Insufficient evidence supporting efficacy in relapsed disease 6. A 65-year-old patient with relapsed Non-Hodgkin Lymphoma (NHL) presents to your clinic. The patient has previously undergone chemotherapy and autologous stem cell transplant but now exhibits progressive disease. Based on emerging therapies, which of the following would be the most appropriate next step in treatment? * A. Administer a tyrosine kinase inhibitor targeting NHL-specific pathways B. Consider bispecific T-cell engager therapy to activate T-cell-mediated tumor killing C. Initiate supportive care and reassess in three months D. Proceed with allogeneic stem cell transplantation as the only remaining option Submit If you are human, leave this field blank. Δ
